Medicare Enrolled
Dr. Nathan Graves, M.D.
Urology Physician · Grapevine, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Graves from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Graves?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Graves
Dr. Nathan Graves is an urology physician in Grapevine, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Graves performed 116,572 Medicare services across 3,017 unique beneficiaries.
Between the years covered by Open Payments, Dr. Graves received a total of $2,897 from 35 pharmaceutical and/or device companies across 167 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Graves is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in TX
$2,897 industry payments
Medicare Practice Summary
Medicare Utilization ↗116,572
Medicare services
Top 1% in TX for urology physician
3,017
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,135 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Testosterone injection An injection of testosterone cypionate, a form of testosterone hormone. The dose is measured in milligrams. |
105,400 | $0 | $0 |
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
4,609 | $34 | $50 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
770 | $34 | $50 |
| Urinalysis with microscopic exam A urine test performed manually that includes examining the sample under a microscope to check for abnormalities. |
598 | $3 | $16 |
| Creatinine test (kidney function) A blood test that measures the amount of creatinine to assess kidney function or detect muscle injury. |
597 | $5 | $20 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
443 | $11 | $40 |
| Haemophilus influenzae antibody test A blood test that measures the level of antibodies to the Haemophilus influenzae bacteria. This analysis helps determine if the body has developed an immune response to this respiratory bacteria. |
385 | $16 | $25 |
| TB DNA amplification test A laboratory test that uses DNA amplification to detect the presence of tuberculosis bacteria in a sample. |
385 | $40 | $50 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
385 | $34 | $50 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
385 | $34 | $50 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
385 | $34 | $50 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
275 | $138 | $367 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
252 | $0 | $10 |
| Limited retroperitoneal ultrasound A focused ultrasound exam of the area behind the abdominal cavity to evaluate specific structures. |
228 | $34 | $201 |
| Complete pelvic ultrasound An imaging test using sound waves to create pictures of the organs and structures within the pelvis. |
227 | $82 | $250 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
161 | $102 | $340 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
156 | $0 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
144 | $97 | $270 |
| Electronic assessment of bladder emptying A test that uses electronic monitoring to evaluate how well the bladder empties urine. |
139 | $6 | $30 |
| Other procedure on male genital system A surgical or medical intervention performed on the male genital organs that does not fall under other specific categories. |
134 | $152 | $400 |
| Non-needle muscle activity measurement of bladder and bowel openings This procedure measures and records the electrical activity of muscles at the bladder and bowel openings without using needles. |
128 | $27 | $325 |
| Abdominal X-ray, 1 view An X-ray image of the abdomen taken from a single angle to visualize internal structures. |
65 | $24 | $150 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
54 | $190 | $500 |
| Injection, garamycin, gentamicin, up to 80 mg | 46 | $2 | $15 |
| Shock wave crushing of kidney stones A procedure that uses shock waves to break kidney stones into smaller pieces so they can pass more easily from the body. |
30 | $430 | $3,000 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
30 | $66 | $198 |
| Meperidine hydrochloride injection, per 100 mg An injection of meperidine hydrochloride, a pain-relieving medication, measured in 100 mg increments. |
29 | $6 | $25 |
| New patient office visit, complex (60-74 min) | 25 | $170 | $450 |
| Prostate tissue destruction using microwave heat This procedure destroys prostate tissue by applying heat generated through microwave energy. |
24 | $1,136 | $5,700 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
23 | $100 | $250 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
20 | $89 | $300 |
| Urethral dilation using endoscope A procedure to widen the urethra using a thin, lighted tube called an endoscope. This helps to open a narrowed urethral passage. |
17 | $243 | $1,010 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
12 | $133 | $342 |
| Endoscopic destruction of bladder, urethra, or gland tissue A procedure that uses an endoscope to destroy tissue in the bladder, urethra, or surrounding glands. |
11 | $608 | $1,982 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$2,897
Total received (2018-2024)
Avg $414/year across 7 years
Bottom 48% in TX for urology physician
35
Companies
167
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,797 (96.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (3.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$195
2023
$161
2022
$499
2021
$684
2020
$593
2019
$353
2018
$413
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$451
Antares Pharma, Inc.
$400
PFIZER INC.
$228
ABBVIE INC.
$211
Clarus Therapeutics Inc.
$157
Accord Healthcare, Inc.
$126
Janssen Biotech, Inc.
$123
Endo Pharmaceuticals Inc.
$109
Myovant Sciences Inc.
$104
Boston Scientific Corporation
$104
Blue Earth Diagnostics Limited
$95
Merck Sharp & Dohme Corporation
$84
AbbVie, Inc.
$76
Mission Pharmacal Company
$74
Verity Pharmaceuticals Inc.
$70
BOSTON SCIENTIFIC CORPORATION
$66
AbbVie Inc.
$60
Laborie Medical Technologies Corp.
$36
Retrophin, Inc.
$31
Axonics Modulation Technologies, Inc.
$30
COLOPLAST CORP
$27
Travere Therapeutics, Inc.
$25
MEDIVATION FIELD SOLUTIONS LLC
$25
Axonics, Inc.
$20
Progenics Pharmaceuticals, Inc.
$20
Coloplast Corp
$20
Biocompatibles, Inc.
$17
UROGEN PHARMA, INC.
$16
Olympus America Inc.
$16
Egalet US Inc
$15
Kowa Pharmaceuticals America, Inc.
$14
Zyla Life Sciences, Inc.
$13
Augmenix, Inc.
$12
IsoRay, Inc
$11
NxThera, Inc.
$8
Top 3 companies account for 37.2% of total payments
Associated products mentioned in payments ›
(815) Thiola · AMS · AVEED · Androgel · Axonics · Axonics r-SNM System · Axumin · BOTOX · Brachytherapy Source · CAMCEVI · ENDOUROLOGY · ERLEADA · Erleada · Foot Switch for UES-40 · GENERAL THERAPIES · GENERAL BPH · GREENLIGHT · General - Therapies · JATENZO · JELMYTO · KEYTRUDA · LUPRON DEPOT · Lupron · Lupron Depot · MYRBETRIQ · NOCDURNA · ORGOVYX · OTREXUP · Otrexup · POSLUMA · PYLARIFY · REZUM · ReTrace · Rezum · SEGLENTIS · SPRIX · SpaceOAR · TOVIAZ · Trelstar · Uribel · Urocit-K · VISUAL-ICE · XIAFLEX · XTANDI · XYOSTED
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Urology physicians within 10 mi
180
Per 100K population
8.4
County median income
$81,905
Nearest hospital
BAYLOR SCOTT & WHITE MEDICAL CENTER GRAPEVINE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Graves is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Graves experienced with testosterone injection?
Based on Medicare claims data, Dr. Graves performed 105,400 testosterone injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Graves receive payments from pharmaceutical companies?
Yes. Dr. Graves received a total of $2,897 from 35 companies across 167 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Graves's costs compare to other urology physicians in Grapevine?
Dr. Graves's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Graves) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Grapevine
Browse urology physicians in Grapevine ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in TX
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in TX
Which TX urology physicians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Antares Pharma, Inc. Payments to Doctors
See all physicians who received payments from Antares Pharma, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology